Table 3 Patient demographics for the medication cohort
Characteristics | No diabetes (n = 393) | T2DM (n = 367) | Standardised difference (%) | P value |
|---|---|---|---|---|
Age, median (IQR) | 63.9 (54.4, 73.0) | 66.6 (59.9, 72.7) | 0.5 | 0.95 |
Gender (male) | 230 (58.5%) | 224 (61.0%) | 1.5 | 0.84 |
Country of birth (Australian) | ||||
Non-Australian | 92 (23.4%) | 108 (29.4%) | 0.7 | 0.85 |
Australian | 289 (73.5%) | 239 (65.1%) | 0.2 | Â |
Unknown | 12 (3.1%) | 20 (5.4%) | 2.1 | Â |
SEIFA Index, median (IQR) | 6.0 (4.0, 7.0) | 6.0 (4.0, 7.0) | 1.2 | 0.88 |
Stage of CKD | ||||
No known CKD | 381 (96.9%) | 337 (91.8%) | 0.3 | 0.97 |
CKD stage 2 | 1 (0.3%) | 2 (0.5%) | 4.9 | Â |
CKD stage 3 | 5 (1.3%) | 21 (5.7%) | 4.0 | Â |
CKD stage 4 | 2 (0.5%) | 3 (0.8%) | 1.5 | Â |
CKD stage 5 | 4 (1.0%) | 4 (1.1%) | 1.0 | Â |
Indication for angiogram | ||||
Chest pain | 93 (23.7%) | 91 (24.8%) | 0.6 | 0.94 |
History of acute coronary event | 45 (11.5%) | 42 (11.4%) | Â | Â |
Breathlessness | 42 (10.7%) | 32 (8.7%) | Â | Â |
Positive non-invasive test | 144 (36.6%) | 146 (39.8%) | Â | Â |
Other | 69 (17.6%) | 56 (15.3%) | Â | Â |
Year of angiogram | ||||
2013 | 57 (14.5%) | 37 (10.1%) | 1.6 | 0.84 |
2014 | 46 (11.7%) | 50 (13.6%) | Â | Â |
2015 | 53 (13.5%) | 56 (15.3%) | Â | Â |
2016 | 54 (13.7%) | 56 (15.3%) | Â | Â |
2017 | 60 (15.3%) | 55 (15.0%) | Â | Â |
2018 | 60 (15.3%) | 51 (13.9%) | Â | Â |
2019 | 63 (16.0%) | 62 (16.9%) | Â | Â |
Valvular disease | 39 (9.9%) | 25 (6.8%) | 2.6 | 0.77 |
Peripheral vascular disorders | 14 (3.6%) | 5 (1.4%) | 4.3 | 0.71 |
Congestive heart failure | 32 (8.1%) | 23 (6.3%) | < 0.01 | 1.00 |
Cardiac arrhythmia | 31 (7.9%) | 27 (7.4%) | 0.9 | 0.91 |
Hypertension | 41 (10.4%) | 53 (14.4%) | 1.4 | 0.86 |